Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia

被引:10
|
作者
Hsu, HC [1 ]
Lee, YT [1 ]
Yeh, HT [1 ]
Chen, MF [1 ]
机构
[1] Natl Taiwan Univ, Med Ctr, Dept Internal Med Cardiol, Taipei, Taiwan
来源
关键词
D O I
10.1067/mlc.2001.114991
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Recent studies suggest that both oxidized very-low-density lipoprotein (VLDL) and oxidized high-density lipoprotein (HDL) may play a role in the pathogenesis of atherosclerosis. Gemfibrozil is widely used and is reported to decrease VLDL levels and increase HDL levels. The aim of this study was to investigate the effect of gemfibrozil on the chemical composition and oxidative susceptibility of VLDL and HDL and their relationship with atherosclerosis, Twenty patients with hypertriglyceridemia were treated with 300 mg gemfibrozil, 3 times daily, for 12 weeks. Venous blood samples were collected before treatment, at the end of treatment, and 4 weeks after the end of treatment. Gemfibrozil effectively lowered concentrations of plasma lipid, apolipoprotein (apo) B, and apo E, The lipid and protein content of VLDL were also decreased, but not by the same extent, The surface-to-core ratio and apo E/apo B ratio of VLDL particles were increased after gemfibrozil treatment. HDL2 cholesteryl ester and HDL3 apo A-ii content were also increased. Gemfibrozil treatment lowered levels of lipid peroxides in both VLDL and HDL particles. The susceptibility of VLDL to oxidation was unchanged, whereas maximal peroxide production was decreased. The oxidative susceptibility of both HDL2 and HDL3 decreased with gemfibrozil treatment. These results indicate that after gemfibrozil treatment, VLDL and HDL particles in patients with hypertriglyceridemia are less atherogenic, which may explain why gemfibrozil treatment is beneficial in terms of coronary heart disease in hypertriglyceridemia.
引用
收藏
页码:414 / 421
页数:8
相关论文
共 50 条
  • [31] Impact of body composition on very-low-density lipoprotein-triglycerides kinetics
    Gormsen, Lars C.
    Nellemann, Birgitte
    Sorensen, Lars P.
    Jensen, Michael D.
    Christiansen, Jens S.
    Nielsen, Soren
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2009, 296 (01): : E165 - E173
  • [32] Effect of endotoxin on very-low-density lipoprotein metabolism in rat heart
    Hole, DG
    Bennett, MJ
    Evans, RD
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1998, 26 (03) : S204 - S204
  • [33] RADICAL-MEDIATED OXIDATION OF ISOLATED HUMAN VERY-LOW-DENSITY LIPOPROTEIN
    MOHR, D
    STOCKER, R
    ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (07): : 1186 - 1192
  • [34] Very-low-density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro
    Amadottir, M
    Dallongeville, J
    Fruchart, JC
    NilssonEhle, P
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (06): : 686 - 690
  • [35] HIGH-DENSITY LIPOPROTEIN INFUSION IN TANGIER DISEASE - ALTERATION OF LOW-DENSITY LIPOPROTEIN COMPOSITION
    HERBERT, PN
    BAUSSERMAN, LL
    HEINEN, RJ
    CLINICAL RESEARCH, 1978, 26 (03): : A561 - A561
  • [36] COMPARISON OF GEMFIBROZIL AND LOVASTATIN IN PATIENTS WITH HIGH LOW-DENSITY-LIPOPROTEIN AND LOW HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS
    MCKENNEY, JM
    BARNETT, MD
    WRIGHT, JT
    PROCTOR, JP
    ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (09) : 1781 - 1787
  • [37] Distribution of Low-Density Lipoprotein and High-Density Lipoprotein Subclasses in Patients With Sarcoidosis
    Vekic, Jelena
    Zeljkovic, Aleksandra
    Jelic-Ivanovic, Zorana
    Spasojevic-Kalimanovska, Vesna
    Spasic, Slavica
    Videnovic-Ivanov, Jelica
    Ivanisevic, Jasmina
    Vucinic-Mihailovic, Violeta
    Gojkovic, Tamara
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (12) : 1780 - 1787
  • [38] Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial
    Otvos, JD
    Collins, D
    Freedman, DS
    Shalaurova, I
    Schaefer, EJ
    McNamara, JR
    Bloomfield, HE
    Robins, SJ
    CIRCULATION, 2006, 113 (12) : 1556 - 1563
  • [39] PREDNISONE INCREASES VERY LOW-DENSITY LIPOPROTEIN AND HIGH-DENSITY LIPOPROTEIN IN HEALTHY-MEN
    ETTINGER, WH
    HAZZARD, WR
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1988, 37 (11): : 1055 - 1058
  • [40] DETECTION OF NEW EPITOPES FORMED UPON OXIDATION OF LOW-DENSITY LIPOPROTEIN, LIPOPROTEIN(A) AND VERY-LOW-DENSITY LIPOPROTEIN - USE OF AN ANTISERUM AGAINST 4-HYDROXYNONENAL-MODIFIED LOW-DENSITY LIPOPROTEIN
    JURGENS, G
    ASHY, A
    ESTERBAUER, H
    BIOCHEMICAL JOURNAL, 1990, 265 (02) : 605 - 608